随着人才竞争日益激烈，高校的研究计划也越发的昂贵，这使得企业有更多的机会“入侵”校园。美国大多数的药剂公司和整个学术部门签订了合同，实质上是一种学术垄断。据美国教育委员会主席Stanley O.Ikenberry研究发现，特别是在医学教育方面，过去10年，医学教育的质量和性质、决策者们的战略性选择更多的是被市场所左右，而不是从医学教育发展的长远目标出发。

With competition for talented people becoming fiercer， the budget of higher institutions of learning for research rose to a new height， giving more opportunities for the enterprises to get into schools. Most of the pharmaceutical companies have signed contracts with the whole academic circle， which is intrinsically a kind of academic monopoly. Stanley O.Ikenberry， president of the Commission of Education of the United States， discovered in his research that it was the market instead of the consideration for a long-term development of the medical science that determined the quality and nature of the medical education， and influenced the strategic choice.